Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02066129 · ClinicalTrials.gov registry record · Phase 3
Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations
A Phase 3 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 254
- Enrollment target
NCT02066129: Completed Phase 3 study, sponsored by Milton S. Hershey Medical Center.
NCT02066129 is a Phase 3 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 254 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02066129, a Phase 3 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 254 participants
- Enrollment target
Study Summary
The objective of this study is to determine whether, in children receiving low-dose inhaled corticosteroids (ICS), quintupling the dose of inhaled corticosteroids at the onset of symptoms previously associated with upper respiratory illnesses and subsequent asthma exacerbations reduces the rate of severe asthma exacerbations treated with oral corticosteroids.
Primary Outcome
The primary outcome is the rate of severe asthma exacerbations treated with oral corticosteroids during the 48 week treatment period.
Interventions
- DRUG Fluticasone 44 mcg
- DRUG Fluticasone 220 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-04-21 |
| Phase | Phase 3 |
What the finished NCT02066129 record still lists
NCT02066129 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 2 interventions - of which Fluticasone 44 mcg is the first listed.
NCT02066129 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02066129 about?
NCT02066129 is a clinical study titled "Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations". The objective of this study is to determine whether, in children receiving low-dose inhaled corticosteroids (ICS), quintupling the dose of inhaled corticosteroids at the onset of symptoms previously associated with upper respiratory illnesses and subsequent asthma exacerbations reduces the rate of s...
What is the current status of trial NCT02066129?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 254 participants. The study started on 2014-07. Estimated completion is 2017-04-21.
What interventions are being tested in trial NCT02066129?
The interventions under investigation include: Fluticasone 44 mcg (DRUG), Fluticasone 220 mcg (DRUG).
Who is sponsoring clinical trial NCT02066129?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02066129's enrollment target sits among peer trials
254 1245th of 2000 higher than 755 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia